Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Transfusion. 2020 Oct 18;61(1):108–123. doi: 10.1111/trf.16141

FIGURE 5.

FIGURE 5

Testosterone replacement therapy modulates RBC susceptibility to hemolysis in cold storage. RBC concentrates from testosterone-treated donors (TRT) and matched controls (no TRT) were stored (1-6°C) for six weeks and tested for storage or stress-induced hemolysis as described in Materials and Methods. Cohort 1: therapeutic donations by five TRT patients and three age, sex, and race-matched controls (Vitalant Pittsburgh). Cohort 2: allogenic donations by three TRT donors and three age, sex, blood type, and race-matched controls (Vitalant Denver). A and D: percent spontaneous storage hemolysis. B and E: percent osmotic hemolysis. C and F: percent AAPH-induced oxidative hemolysis. Significant (P < 0.05) differences between TRT and matched controls were observed in osmotic hemolysis as summarized in Table S4